We performed an enzymatic assay to determine the inhibition of ASK1 by CS17919 compared with GS‐4997, a Phase III ASK1 inhibitor in the treatment of advanced NASH and DKD. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.